SLC5A2 and lung adenocarcinoma: Notably, their efficacy may vary depending on tumor metabolic phenotype and stage; for instance, SGLT2 seems to be more represented in precancerous lesions and early, well-differentiated lung adenocarcinoma in mice, suggesting that SGLT2 is a diagnostic and therapeutic target with a greater benefit for early-stage lung adenocarcinoma than in advanced disease [136,147].